News and Trends 28 Sep 2022 Primary Aldosteronism Foundation creates alliance to tackle hypertension The Primary Aldosteronism Foundation has announced the creation of a multi-stakeholder alliance to drive diagnosis and treatment of primary aldosteronism, a common cause of hypertension. Among the partners is Mineralys Therapeutics, Inc, a biopharmaceutical company developing a novel therapy for the treatment of hypertension. The initiative will facilitate the design and implementation of interventions to […] September 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […] September 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Optics11 Life receives €5 million in funding for drug development and rollout of products Expanded offerings for drug development and regenerative medicines will be the focus of €5 million ($4.8 million) funding raised by Optics11 Life. The funding from Forward.ONE and returning investor, Value Creation Capital, was announced today (September 28) and will support the rollout of new products applying the company’s technology for experiments at scale requiring high-throughput […] September 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 28 Sep 2022 How the alternative protein space aims to address food waste Food waste impacts the whole of society, including the field of alternative protein. Nick Cooney, managing partner of Lever VC, explains how companies and investors in the space aim to tackle the global problem. This week, the UN and its food security-focused arm, the Food and Agriculture Organization, celebrate the International Day of Awareness of […] September 28, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Spoonshot on how foodtech can reduce food waste With the International Day of Awareness of Food Loss and Waste just around the corner, Labiotech caught up with Spoonshot co-founder and CEO Kishan Vasani to find out how the foodtech sector can tackle food waste. Spoonshot is a software platform for food and beverage professionals that delivers category intelligence by leveraging data from more […] September 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2022 Protocol for treatment of neurotrophic keratopathy submitted to FDA by ReGenTree Protocol for a second phase 3 clinical trial for a treatment for neurotrophic keratopathy (NK) – a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, has been submitted. RegeneRx Biopharmaceuticals reported that its U.S. joint venture partner and licensee, HLB Therapeutics, together called ReGenTree, made the submission to the U.S. Food and […] September 27, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke. Acticor Biotech, a clinical stage biotech company, made the announcement today (September 26). The patient was enrolled at the CHI Memorial Stroke and Neuroscience Center, Chattanooga, Tennessee, by neurologist, Ruchir Shah. Significant potential He said: “I am very […] September 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 TAU Systems to build new generation of compact particle accelerators after $15M investment TAU Systems has raised $15 million in seed investment to bring particle accelerators to a multitude of users by harnessing the latest laser technology to make electrons surf on three-dimensional plasma waves and accelerate them to ultra-high energies. The news is significant as, until now, high-energy particle accelerators have been limited to countries and governmental […] September 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Commercial launch of monkeypox PCR test for research use in laboratories worldwide A newly developed molecular polymerase chain reaction (PCR) test for monkeypox is now commercially available globally for research use only applications. Becton, Dickinson and Company (BD) and CerTest Biotec made the announcement today (September 26) that the test can be used in laboratories. The teams leveraged the BD MAX System open architecture reagent suite to develop […] September 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 26 Sep 2022 Rapid diagnostics are needed to tackle antimicrobial resistance As the antimicrobial resistance (AMR) crisis grows, bacterial infections are becoming harder to treat. Chris Lock, vice president of R&D at the mass spectrometry specialist SCIEX, discusses how rapid diagnostics can help doctors wield antimicrobial treatments more effectively. The AMR crisis is growing increasingly severe, resulting in superbugs that are able to shrug off multiple […] September 26, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Surge raises $2.6M in funding for technology and secures exclusive licensing agreement Surge, a biotech and artificial intelligence innovator that produces technology to decode immune fingerprints, has received $2.6 million in funding. The technology accurately identifies patients at risk before surgery and enables physicians to quickly forecast the risk of postoperative complications. The funding round was co-led by HCVC, a global early-stage fund dedicated to high-potential […] September 26, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Study data for glioblastoma treatment confirms safety and tolerability profile The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […] September 22, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email